Elliot Stieglitz

MD

Pediatric hematologist-oncologist
Leukemia researcher and Scrabble enthusiast

Dr. Elliot Stieglitz is a pediatric hematologist-oncologist who cares for children with difficult-to-treat leukemias (blood cancers most often involving white blood cells).

Stieglitz's laboratory research focuses on juvenile myelomonocytic leukemia (JMML), which is often difficult to diagnose and treat. His research has found that the course of JMML varies among patients and that DNA profiling can predict which patients will benefit from certain new treatments. He leads clinical trials – studies that evaluate new therapies – of targeted treatments for patients with JMML, and his research has received funding from the National Institutes of Health, V Foundation, Pediatric Cancer Research Foundation, Cancer League, St. Baldrick's Foundation and Alex's Lemonade Stand Foundation.

Stieglitz earned his medical degree from the Renaissance School of Medicine at Stony Brook University. He completed a residency in pediatrics at New York – Presbyterian Weill Cornell Medical Center and a fellowship in pediatric hematology-oncology at UCSF.

  • Education

    Renaissance School of Medicine at Stony Brook University, MD, 2008

  • Residencies

    Weill Cornell Medicine, Pediatrics, 2011

  • Fellowships

    UCSF, Pediatric Hematology and Oncology, 2014

  • Board Certifications

    Pediatric Hematology-Oncology, American Board of Pediatrics

    Pediatrics, American Board of Pediatrics

  • Academic Title

    Associate Professor

Where I see patients (1)

    Selected research

    See all research
    Decorative Caduceus

    Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...

    Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...

    Recruiting

    More about this study
    Decorative Caduceus

    A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or R...

    Regimen A Cycle 1 will be used for determination of recommended phase 2 dose (RP2D)-lymphoid (L) directed chemotherapy block. A patient will be considered as being evaluable for DLT if: (1) the patient receives at least 66 doses o...

    Recruiting

    More about this study
    Decorative Caduceus

    The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in...

    The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confiden...

    Recruiting

    More about this study
    Decorative Caduceus

    Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or...

    The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated.

    Recruiting

    More about this study
    See all clinical trials

    Contact me

    Smell the roses

    Wander outside into our Butterfly Garden in Oakland and our healing gardens at Mission Bay.

    Share